NCT02912260Phase 2Completed

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2017-10-25Actual
Enrollment · participants125Actual
Source updated2025-12-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF. After: Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF).

Primary completion date changed

Before: Oct 2017. After: 25 Oct 2017.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source